NRx Pharmaceuticals Inc (NRXPW) - Total Liabilities
Based on the latest financial reports, NRx Pharmaceuticals Inc (NRXPW) has total liabilities worth $25.72 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NRx Pharmaceuticals Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how NRx Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See NRx Pharmaceuticals Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
NRx Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of NRx Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ethernity Networks Ltd
LSE:ENET
|
UK | GBX3.20 Million |
|
Seed Capital Solutions Plc
LSE:SCSP
|
UK | GBX28.00K |
|
NLS Pharmaceutics AG
NASDAQ:NLSPW
|
USA | $1.46 Million |
|
PetroFrontier Corp
V:PFC
|
Canada | CA$24.14 Million |
|
Tarrina Resources Limited
AU:TR8
|
Australia | AU$1.04 Million |
|
Adheris Health Limited
AU:AHE
|
Australia | AU$38.79 Million |
|
Us1 Critical Minerals Limited
AU:USC
|
Australia | AU$168.75K |
Liability Composition Analysis (2017–2025)
This chart breaks down NRx Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NRXPW stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NRx Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NRx Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of NRx Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $28.89 Million | +7.51% |
| 2024-12-31 | $26.87 Million | +41.09% |
| 2023-12-31 | $19.05 Million | +3.48% |
| 2022-12-31 | $18.41 Million | +54.38% |
| 2021-12-31 | $11.92 Million | -74.48% |
| 2020-12-31 | $46.71 Million | +1714.62% |
| 2019-12-31 | $2.57 Million | +104.72% |
| 2018-12-31 | $1.26 Million | +1249.57% |
| 2017-12-31 | $93.17K | -- |
About NRx Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone… Read more